Formulation Featured Articles

  1. In Vivo Manufacturing: When The Body Becomes The Bioreactor 5/15/2026

    Breakthrough therapies are reshaping medicine, but manufacturing complexity is holding them back. Discover how rethinking production and delivery could expand reach and improve patient experience.

  2. Can A Biotech Create A CDMO Market? 5/11/2026

    Can a biotech create a CDMO market? GeoVax, an infectious disease/oncology biotech, may have just done so. David Dodd, CEO, believes we should all concentrate more on whether the outsourcing model can align with evolving technology platforms. Both sponsors and CDMOs may need to change things up.

  3. Chirality In Drug Development: From Racemic Mixtures To Enantiopure Substances 5/6/2026

    Chiral crystallization enables efficient production of enantiopure drug substances, improving pharmacological control and safety while supporting scalable, cost‑effective small molecule development.

  4. Optimising Solubility: Selecting The Right Technology For Early Drug Development 5/6/2026

    Discover how selecting the right solubility‑enhancing technology improves early exposure, supports flexible dosing, and lays a strong foundation for downstream oral drug development.

  5. Why Dilution Gets Tricky: The Role Of Measurement Variability 5/5/2026

    Dilution's effects on downstream processes and final formulation is often understated. A statistical framework can quantify measurement uncertainty's impacts.

  6. How Rheology Ensures Effective Quality Control 5/1/2026

    Rheology connects formulation science to manufacturing reality. By tracking how drugs flow and respond to stress, teams can prevent batch variability and protect dosage performance.

  7. Advancing Formulation Strategies for Complex Drug Products 4/30/2026

    An event-focused overview examining how formulation development and stability strategies support robust, scalable drug products discussed at the DDF Summit Berlin.

  8. Strengthening Drug Product CMC through Drug Product Science | AAPS 4/27/2026

    At AAPS, drug product experts discuss how formulation, stability, and analytical services enable robust CMC strategies, reduce development risk, and support confident regulatory decision‑making.

  9. Managing CMC Risk For Complex Peptide And Nucleic Acid Therapeutics 4/24/2026

    At TIDES USA 2026, experts discuss how formulation science, stability strategies, and advanced analytics help reduce CMC risk and enable confident development of peptide and nucleic acid therapeutics.

  10. Expanding The IV → SC Framework: What Reformulation Really Means 4/22/2026

    IV → SC is a system design challenge. Success depends on aligning formulation, device, manufacturing, and clinical strategy early to avoid costly failures and redesigns.